Companies Sera Prognostics
Sera Prognostics (SERA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sera Prognostics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers25th pct.Of 18 peer CEOs
CEO pay, last three years
- $2,196,283FY2023
- $693,398FY2024
- $2,033,811FY2025
CEO total pay was $2,033,811 in fiscal 2025, up from $693,398 in fiscal 2024.
FY2025: salary $607,000 · bonus $0 · stock awards $526,718 · option awards $493,971
Executives and directors
Paul Kearney · Chief Data OfficerZhenya Lindgardt · CEOJohn Boniface · Chief Scientific OfficerGregory C. Critchfield, M.D., M.S · Independent DirectorJane F. Barlow, M.D · Independent DirectorJeffrey T. Elliott · Independent DirectorJoshua Phillips · Independent DirectorKim Kamdar, Ph.D · Chair of the BoardMansoor Raza Mirza, M.D · Independent DirectorMarcus Wilson, Pharm.D · Former director (through FY2025)Ryan Trimble · Former director (through FY2025)Sandra A.J. Lawrence · Independent Director
Frequently asked questions
Who was the highest-paid executive at Sera Prognostics in fiscal 2025?
As disclosed, Zhenya Lindgardt (President and Chief Executive Officer) was the highest-paid executive at Sera Prognostics in fiscal 2025, with total compensation of $2,033,811.
How does Sera Prognostics's chief executive pay compare to its disclosed peer group?
As disclosed, Zhenya Lindgardt's total compensation ranked at the 25th percentile of Sera Prognostics's disclosed peer group.
How much does Sera Prognostics spend in total on board compensation for fiscal 2025?
As disclosed, Sera Prognostics reported total board compensation of $642,313 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Zhenya Lindgardt | $607,000 | $0 | $526,718 | $493,971 | $392,122 | $0 | $14,000 | $2,033,811 |
| President and Chief Executive Officer | ||||||||
| John Boniface | 439,130 | 0 | 197,442 | 186,970 | 166,650 | 0 | 14,000 | 1,004,192 |
| Chief Scientific Officer | ||||||||
| Paul Kearney | 426,075 | 0 | 197,442 | 186,970 | 160,204 | 0 | 14,000 | 984,691 |
| Chief Data Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Zhenya Lindgardt | $2,033,811 | $693,398 | $2,196,283 | ↑ +1,340,413 |
| John Boniface | 1,004,192 | 431,282 | 871,963 | ↑ +572,910 |
| Paul Kearney | 984,691 | 847,042 | — | ↑ +137,649 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our general executive compensation philosophy is to provide programs that attract, motivate, reward and retain highly qualified executives and motivate them to pursue our corporate objectives while encouraging the creation of long-term value for our stockholders.
| CEO STI target (% of salary) | 68% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Boniface | OPTION | — | — | — | — | — | $186,970 |
| Paul Kearney | RSU | — | — | — | — | — | 197,442 |
| Zhenya Lindgardt | OPTION | — | — | — | — | — | 493,971 |
| John Boniface | RSU | — | — | — | — | — | 197,442 |
| Zhenya Lindgardt | RSU | — | — | — | — | — | 526,718 |
| Paul Kearney | OPTION | — | — | — | — | — | 186,970 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Boniface | $197,442 | $0 | $186,970 | 0.0% |
| Paul Kearney | 197,442 | 0 | 186,970 | 0.0% |
| Zhenya Lindgardt | 526,718 | 0 | 493,971 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Kearney | Option | 3,043 | 3.75 | — |
| Paul Kearney | Option | 7,906 | 3.8 | — |
| Paul Kearney | RSU | 8,000 | — | 23,600 |
| John Boniface | Option | 10,906 | 3.8 | — |
| John Boniface | RSU | 11,050 | — | 32,598 |
| John Boniface | Option | 12,171 | 3.75 | — |
| John Boniface | RSU | 38,196 | — | 112,678 |
| Paul Kearney | RSU | 38,196 | — | 112,678 |
| John Boniface | Option | 55,096 | 4.2 | — |
| Paul Kearney | Option | 55,096 | 4.2 | — |
| Zhenya Lindgardt | RSU | 103,122 | — | 304,210 |
| Zhenya Lindgardt | Option | 147,371 | 4.15 | — |
| Zhenya Lindgardt | RSU | 300,000 | — | 885,000 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey T. ElliottIndependent · Audit · Compensation · Newly elected | $35,792 | $120,000 | $120,000 | $0 | $0 | $275,792 |
| Kim Kamdar, Ph.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance | 82,000 | 24,954 | 24,954 | 0 | 0 | 131,908 |
| Sandra A.J. LawrenceIndependent · Audit (Chair) | 50,000 | 24,954 | 24,954 | 0 | 0 | 99,908 |
| Joshua PhillipsIndependent · Audit · Compensation | 47,500 | 24,954 | 24,954 | 0 | 0 | 97,408 |
| Jane F. Barlow, M.DIndependent · Nominating/Governance (Chair) | 43,500 | 24,954 | 24,954 | 0 | 0 | 93,408 |
| Mansoor Raza Mirza, M.DIndependent · Nominating/Governance | 39,000 | 24,954 | 24,954 | 0 | 0 | 88,908 |
| Gregory C. Critchfield, M.D., M.SIndependent | 35,000 | 24,954 | 24,954 | 0 | 0 | 84,908 |
| Ryan TrimbleIndependent · Audit · Departed during FY | 21,250 | — | — | 0 | 0 | 21,250 |
| Marcus Wilson, Pharm.DIndependent · Not standing for re-election · Departed during FY | 18,547 | — | — | 0 | 0 | 18,547 |
| Zhenya LindgardtEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | $120,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $372,589 |
| Equity awards (grant-date value) | $269,724 |
| All other compensation | $0 |
| Total cost of the board | $642,313 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sera Prognostics as a peer
Companies that benchmark against SERA
No companies currently name SERA as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
GNLX GeneluxMXCT MaxCyteMYGN Myriad GeneticsBDSX Biodesix Cassava SciencesXGN Exagen ImmunicLUCD Lucid DiagnosticsUTMD Utah Medical ProductsIMDX Insight Molecular DiagnosticsSTIM NeuroneticsOBIO Orchestra BioMed HoldingsPSNL PersonalisQTRX QuanterixQSI Quantum-Si incorporatedSEER SeerSGHT Sight SciencesVRCA Verrica Pharmaceuticals
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Myriad Genetics | 2025 | Samraat Raha | $856,901 | $3,989,729 | $0 | $814,660 | $5,686,740 |
| 2 | Quanterix | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 3 | Neuronetics | 2025 | Keith Sullivan | 728,000 | 3,208,750 | 0 | 412,776 | 4,365,064 |
| 4 | Personalis | 2025 | Christopher Hall | 618,000 | 853,050 | 1,784,728 | 247,200 | 3,505,978 |
| 5 | Quantum-Si incorporated | 2025 | Jeffrey Hawkins | 620,833 | 2,000,000 | 0 | 562,500 | 3,183,693 |
| 6 | MaxCyte | 2025 | Maher Masoud | 590,000 | 1,143,275 | 625,300 | 313,290 | 2,687,657 |
| 7 | Insight Molecular Diagnostics | 2025 | Joshua Riggs | 472,293 | 599,999 | 1,332,000 | 0 | 2,594,786 |
| 8 | Orchestra BioMed Holdings | 2025 | David Hochman | 595,000 | 791,399 | 290,575 | 572,009 | 2,261,233 |
| 9 | Biodesix | 2025 | Scott Hutton | 643,404 | 356,849 | 524,437 | 710,280 | 2,238,470 |
| 10 | Sera Prognostics | 2025 | Zhenya Lindgardt | 607,000 | 526,718 | 493,971 | 392,122 | 2,033,811 |
| 11 | Sight Sciences | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
| 12 | Exagen | 2025 | John Aballi | 540,000 | 402,750 | 203,018 | 237,600 | 1,400,868 |
| 13 | Lucid Diagnostics | 2025 | Lishan Aklog | 300,000 | 447,000 | 0 | — | 897,000 |
| 14 | Utah Medical Products | 2025 | Kevin Cornwell | 87,000 | 0 | 0 | 246,750 | 341,709 |
| — | Genelux | — | — | — | — | — | — | not in coverage universe |
| — | Seer | — | — | — | — | — | — | not in coverage universe |
| — | Verrica Pharmaceuticals | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sera Prognostics | not disclosed | not disclosed | not disclosed | Compensia |
| Biodesix | not disclosed | not disclosed | not disclosed | not disclosed |
| Exagen | not disclosed | not disclosed | not disclosed | Frederick W. Cook & Co., Inc. |
| Genelux | not disclosed | not disclosed | not disclosed | not disclosed |
| Insight Molecular Diagnostics | not disclosed | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Lucid Diagnostics | not disclosed | not disclosed | not disclosed | Aon |
| MaxCyte | 88.5% | not disclosed | No | Pearl Meyer |
| Myriad Genetics | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Neuronetics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Orchestra BioMed Holdings | not disclosed | not disclosed | not disclosed | FW Cook |
| Personalis | not disclosed | not disclosed | not disclosed | Aon |
| Quanterix | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Quantum-Si incorporated | not disclosed | not disclosed | not disclosed | Aon (January–May 2025); Meridian Compensation Partners (May–December 2025) |
| Seer | not disclosed | not disclosed | not disclosed | not disclosed |
| Sight Sciences | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| Utah Medical Products | not disclosed | Option 100 | not disclosed | not disclosed |
| Verrica Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (37 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Zhenya Lindgardt. DEF 14A, filed 2026-04-24. Section “Compensation Table” · page 41. As printed: 2,033,811. View filing ↗
- Section 01, John Boniface. DEF 14A, filed 2026-04-24. Section “Compensation Table” · page 42. As printed: 1,004,192. View filing ↗
- Section 01, Paul Kearney. DEF 14A, filed 2026-04-24. Section “Compensation Table” · page 42. As printed: 984,691. View filing ↗
- Section 03, John Boniface OPTION. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Kearney RSU. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Zhenya Lindgardt OPTION. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, John Boniface RSU. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Zhenya Lindgardt RSU. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Kearney OPTION. DEF 14A, filed 2026-04-24. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-18. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Jeffrey T. Elliott. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 275,792. View filing ↗
- Section 08, Kim Kamdar, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 131,908. View filing ↗
- Section 08, Sandra A.J. Lawrence. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 99,908. View filing ↗
- Section 08, Joshua Phillips. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 97,408. View filing ↗
- Section 08, Jane F. Barlow, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 93,408. View filing ↗
- Section 08, Mansoor Raza Mirza, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 88,908. View filing ↗
- Section 08, Gregory C. Critchfield, M.D., M.S. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 84,908. View filing ↗
- Section 08, Ryan Trimble. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 21,250. View filing ↗
- Section 08, Marcus Wilson, Pharm.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 18,547. View filing ↗
- Section 08, Zhenya Lindgardt. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 372,589 + equity 269,724 + all other 0 = 642,313, summed across the director compensation table rows.
- Myriad Genetics, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Myriad Genetics's own proxy. As printed: 5,686,740. View filing ↗
- Quanterix, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Quanterix's own proxy. As printed: 5,250,745. View filing ↗
- Neuronetics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Neuronetics's own proxy. As printed: 4,365,064. View filing ↗
- Personalis, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Personalis's own proxy. As printed: 3,505,978. View filing ↗
- Quantum-Si incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Quantum-Si incorporated's own proxy. As printed: 3,183,693. View filing ↗
- MaxCyte, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in MaxCyte's own proxy. As printed: 2,687,657. View filing ↗
- Insight Molecular Diagnostics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Insight Molecular Diagnostics's own proxy. As printed: 2,594,786. View filing ↗
- Orchestra BioMed Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orchestra BioMed Holdings's own proxy. As printed: 2,261,233. View filing ↗
- Biodesix, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Biodesix's own proxy. As printed: 2,238,470. View filing ↗
- Sera Prognostics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sera Prognostics's own proxy. As printed: 2,033,811. View filing ↗
- Sight Sciences, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sight Sciences's own proxy. As printed: 2,005,608. View filing ↗
- Exagen, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Exagen's own proxy. As printed: 1,400,868. View filing ↗
- Lucid Diagnostics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Lucid Diagnostics's own proxy. As printed: 897,000. View filing ↗
- Utah Medical Products, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Utah Medical Products's own proxy. As printed: 341,709. View filing ↗